23andMe Holding Co. is a biotechnology company that specializes in personal genomics and biotechnology research
It offers direct-to-consumer genetic testing services, allowing individuals to explore their ancestry, health risks, and genetic traits through easy-to-use saliva collection kits. The company aims to empower people with insights into their genetic information and provide valuable resources for health-related decision-making. Additionally, 23andMe is involved in pharmaceutical research, leveraging its vast genetic database to facilitate drug discovery and development through collaborations with various biopharmaceutical companies.
23andMe restructures, cutting 40% of its workforce and ending its therapeutic programs to save $35 million annually while exploring strategic alternatives.
Lawyer raises objections to 23andMe's proposed $30 million settlement, arguing it undermines arbitration rights for 5,000 customers following a data breach. The court is set to review the case in late October.
